Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN, TANER; Efe, Orhan; Hasirci, Ahmet; Demirci, Fatih; Buyukhatipoglu, Hakan; Balakan, Ozan; Sarici, Furkan; KERTMEN, NEYRAN; Esin, Ece; AKIN, SERKAN; ATEŞ, ÖZTÜRK; AKSOY, SERCAN; SEVER, ALİ; Altundag, Kadri

doi:10.5301/tj.5000332

Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., ...Daha Fazla

TUMORI J, cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 101 Sayı: 4
Basım Tarihi: 2015
Doi Numarası: 10.5301/tj.5000332
Dergi Adı: TUMORI J
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.418-423
Hacettepe Üniversitesi Adresli: Evet

Özet

Aims and Background: Capecitabine is a potent and safe agent that can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of capecitabine monotherapy as a first-line treatment in human epidermal receptor 2 (HER2)-negative patients with MBC.